HYPERTENSION CONDITIONS
High blood pressure treatment options
Treatment options for high blood pressure to discuss with
your doctor include lifestyle changes, medication, and
procedural options such as renal denervation.
It’s important to be aware of the risk factors for high blood pressure,1 which include:
- Modifiable risk factors – such as unhealthy diets, physical inactivity, tobacco or alcohol consumption, and being overweight.
- Non-modifiable risk factors – such as family history, age over 65 years and co-existing diseases like diabetes or kidney disease.
Lifestyle changes
Lifestyle changes can help lower high blood pressure.1
These include:
- Eating a healthy, low-salt diet
- Losing weight
- Being physically active
- Quitting tobacco
Medication
There are several common blood pressure medicines:1
- ACE inhibitors relax blood vessels and prevent kidney damage.
- Angiotensin-2 receptor blockers (ARBs relax blood vessels and prevent kidney damage.
- Calcium channel blockers relax blood vessels.
- Extra water from the body, lowering blood pressure.
Renal Denervation
The renal denervation blood pressure procedure is an evidence-based, minimally invasive procedure that may be indicated for patients with uncontrolled hypertension.2 Designed to be used in conjunction with lifestyle modifications and medications, it has been shown to help reduce blood pressure.3-6 For some patients, it may also allow the number or dosage of blood pressure medications to be reduced.6-8
*Medtronic provides this listing as a service. We have no vested interest in any specific physicians, nor do we provide any recommendation, assurance, or guarantee with respect to their service. This listing may not be a complete list of all physicians who provide this service. Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.
References
1 World Health Organisation. Hypertension fact sheet. 2025. Available at https://www.who.int/news-room/fact-sheets/detail/hypertension. (Accessed April 14, 2026).
2 Mancia R, Kreutz R, Brunstrom M, et al. European Society of Hypertension 2023 Guidelines for the management of arterial hypertension. Journal of Hypertension 2023, 41:1874–2071
3 Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomized, sham-controlled trial. The Lancet 2020: Published online March 29, 2020.
4 Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet 2018; Jun 9;391(10137): 2346-55.
5 Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet 2017; 390: 2160–70
6 Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet 2022; 399(10234): 1401-10.
7 Schlaich M, Mahfoud F, Williams B, et al. Long-term safety and efficacy of renal denervation with the Symplicity Spyral catheter in the Global SYMPLICITY Registry. Kidney Week 2021.
8 Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. The Lancet. Published online September 2022:S0140673622017871. doi:10.1016/S0140-6736(22)01787-1